Suppr超能文献

抗肥胖药物的发现:进展与挑战。

Anti-obesity drug discovery: advances and challenges.

机构信息

Institute for Diabetes and Obesity, Helmholtz Diabetes Center, Helmholtz Zentrum München, Neuherberg, Germany.

German Center for Diabetes Research (DZD), Neuherberg, Germany.

出版信息

Nat Rev Drug Discov. 2022 Mar;21(3):201-223. doi: 10.1038/s41573-021-00337-8. Epub 2021 Nov 23.

Abstract

Enormous progress has been made in the last half-century in the management of diseases closely integrated with excess body weight, such as hypertension, adult-onset diabetes and elevated cholesterol. However, the treatment of obesity itself has proven largely resistant to therapy, with anti-obesity medications (AOMs) often delivering insufficient efficacy and dubious safety. Here, we provide an overview of the history of AOM development, focusing on lessons learned and ongoing obstacles. Recent advances, including increased understanding of the molecular gut-brain communication, are inspiring the pursuit of next-generation AOMs that appear capable of safely achieving sizeable and sustained body weight loss.

摘要

在过去的半个世纪中,与超重密切相关的疾病的管理取得了巨大的进展,如高血压、成人发病型糖尿病和胆固醇升高。然而,肥胖症本身的治疗已被证明在很大程度上难以治疗,抗肥胖药物(AOM)往往疗效不足且安全性存疑。在这里,我们提供了 AOM 开发历史的概述,重点介绍了经验教训和持续存在的障碍。最近的进展,包括对肠道-大脑分子通讯的深入了解,激发了对新一代 AOM 的追求,这些药物有望安全地实现显著和持续的体重减轻。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c943/8609996/4b842d3dedbb/41573_2021_337_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验